C O M M U N I C A T I O N S
cis/cis phospholanes and sulfate salts) was heated to the appropriate
temperature without solvent in an oil bath under a nitrogen
atmosphere. While 2c and 13c were isolated as completely
epimerized products, the methyl- and methoxymethyl-substituted
compounds, 2a and 13a,13b showed incomplete epimerization
under the same conditions.11 Phospholane 1c was even more
difficult to epimerize despite a higher applied temperature (205 vs
190 °C).
The mechanism for pyramidal inversion-induced epimerization
likely involves a transition state featuring an sp2 phosphorus atom
that is in equilibrium with each form of the phospholane, 9 (cis)
and 13 (trans), as shown in Figure 2. The reaction is driven toward
the more thermodynamically stable trans phospholane, 13. That 9a
and 10a provide relatively lower conversions to cis and cis/cis
phospholanes 13a and 2a may be a function of similar energies of
cis vs trans isomers as a result of lessened steric effects from the
small methyl substituents of each compound.
generality of the two approaches we speculate that these method-
ologies may find applicability to the synthesis of as yet undiscovered
P-chirogenic ligands as well as new synthetic routes to those that
are known already. Furthermore, the use of 2c in the highly
enantioselective rhodium-catalyzed asymmetric hydrogenation of
17 bodes well for broader application of the ligands presented in
this communication.
Acknowledgment. I thank Brian Samas for assistance with
X-ray crystallography of phospholanes. Pfizer, Inc. is acknowledged
for continuing support of this research.
Supporting Information Available: Synthetic procedures, proof
of relative and absolute phospholane stereochemistry, spectral data,
representative determinations of the ratio of phospholane diastereomers,
and methods for converting to and purifying their borane and sulfide
adducts. This material is available free of charge via the Internet at
References
(1) (a) Imamoto, T.; Watanabe, J.; Wada, Y.; Masuda, H.; Yamada, H.;
Tsuruta, H.; Matsukawa, S.; Yamaguchi, K. J. Am. Chem. Soc. 1998, 120,
1635-1636. (b) Yamanoi, Y.; Imamoto, T. J. Org. Chem. 1999, 64, 2988-
2989. (c) Tsuruta, H.; Imamoto, T. Tetrahedron: Asymmetry 1999, 10,
877-882. (d) Miura, T.; Imamoto, T. Tetrahedron Lett. 1999, 40, 4833-
4836. (e) Ohashi, A.; Imamoto, T. Org. Lett. 2001, 3, 373-375. (f) Oohara,
N.; Katagiri, K.; Imamoto, T. Tetrahedron: Asymmetry 2003, 14, 2171-
2175. (g) Tang, W.; Zhang, X. Angew. Chem., Int. Ed. 2002, 41, 1612-
1614. (h) Tang, W.; Wang, W.; Chi, Y.; Zhang, X. Angew. Chem., Int.
Ed. 2003, 42, 3509-3511. (i) Hoge, G.; Wu, H.-P.; Kissel, W. S.; Pflum,
D. A.; Greene, D. J.; Bao, J. J. Am. Chem. Soc. 2004, 126, 5966-5967.
(2) Hoge, G. J. Am. Chem. Soc. 2003, 125, 10219-10227.
(3) Burk, M. J. J. Am. Chem. Soc. 1991, 113, 8518-8519.
(4) (a) Vedejs, E.; Daugulis, O. J. Am. Chem. Soc. 1999, 121, 5813-5814.
(b) Vedejs, E.; Daugulis, O. J. Am. Chem. Soc. 2003, 125, 4166-4173.
(5) (a) Herdeis, C. Synthesis 1986, 232-233. (b) Brunner, H.; Lautenschlager,
H.-J. Synthesis 1989, 706-709. (c) Mori, K. Tetrahedron 1975, 31, 3011-
3012. (d) Ravid, U.; Silverstein, R. M.; Smith, L. R. Tetrahedron 1978,
34, 1449-1452. (e) Nemoto, H.; Nagai, M.; Fukumoto, K. J. Org. Chem.
1985, 50, 2764-2766. (f) Cai, X.; Chorghade, M. S.; Fura, A.; Grewal,
G. S.; Jauregui, K. A.; Lounsbury, H. A.; Scannell, R. T.; Yeh, C. G.;
Young, M. A.; Yu, S. Org. Process Res. DeV. 1999, 3, 73-76.
(6) The terms “cis” and “trans” refer to the arrangement of substituents around
the monophospholane rings to prevent confusion with the arrangement
of the lone pair. The terms “cis/cis”, “cis/trans”, and “trans/trans” refer
to the arrangement of each phospholane ring within one molecule of a
bisphospholane.
Figure 2. Pyramidal inversion mechanism.
To highlight the potential utility of the trans/trans bisphos-
pholanes reported in this communication, ligand 2c was converted
to cationic rhodium complex 16 (Scheme 2). Rhodium complex
16 was then used as a catalyst for the asymmetric hydrogenation
of 17 to form 18. Product 18 was the sole hydrogenation product
with 96% enantiomeric excess. The (S) isomer of 18 is a precursor
to pharmaceutical candidate pregabalin.2,12
Scheme 2. Asymmetric Hydrogenation of a Pregabalin Precursora
(7) In most cases cis and cis/cis diastereomers could be isolated from cis:
trans and cis/cis:cis/trans mixtures via either crystallization or column
chromatography of borane or sulfide adducts of the phosphines as
described in the Supporting Information.
(8) (a) Hommer, H.; Gordillo, B. Phosphorous, Sulfur Silicon 2002, 177,
465-470. (b) Egan, W.; Tang, R.; Zon, G.; Mislow, K. J. Am. Chem.
Soc. 1970, 92, 1442-1444. (c) Cremer, S. E.; Chorvat, R. J.; Chang, C.
H.; Davis, D. W. Tetrahedron Lett. 1968, 55, 5799-5802.
(9) Reviews: (a) Lambert, J. B. Top. Stereochem. 1971, 6, 19-104. (b) Rauk,
A.; Allen, L. C.; Mislow, K. Angew. Chem., Int. Ed. Engl. 1970, 9, 400-
414.
(10) While heating is a requirement for the epimerizations involved in the
current discussion, it is not a requirement for all pyramidal inversions to
occur.
(11) In the cases of incomplete epimerization, most trans and trans/trans
diastereomers could be isolated from cis:trans and cis/trans:trans/trans
mixtures via either recrystallization or column chromatography of borane
or sulfide adducts of the phosphines as described in the Supporting
Information.
a Reagents and conditions: (a) 1. [Rh(COD)2]+ OTf-, MeOH; 2.
recrystallization from THF. (b) 1 mol % 16, MeOH, 30 psi H2, 25 °C, 2 h.
(12) Burk, M. J.; de Konig, P. D.; Grote, T. M.; Hoekstra, M. S.; Hoge, G.;
Jennings, R. A.; Kissel, W. S.; Le, T. V.; Lennon, I. C.; Mulhern, T. A.;
Ramsden, J. A.; Wade, R. A. J. Org. Chem. 2003, 68, 5731-5734.
In conclusion, stereoselective cyclization and epimerization via
pyramidal inversion have been demonstrated as viable routes for
the synthesis of a variety of P-chirogenic phospholanes. Given the
JA048079L
9
J. AM. CHEM. SOC. VOL. 126, NO. 32, 2004 9921